Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04420975 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
A Phase 1 study of Leiomyosarcoma and Myxofibrosarcoma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT04420975 is a Phase 1 study of Leiomyosarcoma and Myxofibrosarcoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 14 participants, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04420975, a Phase 1 study of Leiomyosarcoma and Myxofibrosarcoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with BO-112, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab and BO-112 before surgery may work better in treating patients with soft tissue sarcoma compared to nivolumab alone.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- BIOLOGICAL Nivolumab
- PROCEDURE Definitive Surgical Resection
- BIOLOGICAL Nanoplexed Poly I:C BO-112
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04420975
The ClinicalTrials.gov registry entry for NCT04420975 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 121-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (88% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Leiomyosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT04420975 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04420975 about?
NCT04420975 is a clinical study titled "Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma". This phase I trial studies the side effects of BO-112 when given together with nivolumab before surgery in treating patients with soft tissue sarcoma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the...
What is the current status of trial NCT04420975?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-10-14. Estimated completion is 2028-01-31.
What conditions does trial NCT04420975 study?
This clinical trial studies the following conditions: Leiomyosarcoma, Myxofibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Resectable Soft Tissue Sarcoma, Pleomorphic Rhabdomyosarcoma.
What interventions are being tested in trial NCT04420975?
The interventions under investigation include: Radiation Therapy (RADIATION), Nivolumab (BIOLOGICAL), Definitive Surgical Resection (PROCEDURE), Nanoplexed Poly I:C BO-112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04420975?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04420975 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
RECRUITING · Phase 1
-
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
COMPLETED · Phase 1
-
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
COMPLETED · Phase 1
-
Localized Leiomyosarcoma Biomarker Protocol
RECRUITING
-
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
RECRUITING · Phase 3
-
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.